BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30604291)

  • 1. Lorlatinib: First Global Approval.
    Syed YY
    Drugs; 2019 Jan; 79(1):93-98. PubMed ID: 30604291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
    Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
    Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lorlatinib for the treatment of patients with non-small cell lung cancer.
    Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M
    Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Yang J; Gong W
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First macrocyclic 3
    Basit S; Ashraf Z; Lee K; Latif M
    Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
    Chen J; Houk B; Pithavala YK; Ruiz-Garcia A
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):148-160. PubMed ID: 33449423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
    Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
    Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
    Wu X; Wang Y; Wan S; Zhang J
    J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
    Sun S; Pithavala YK; Martini JF; Chen J
    J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
    Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
    Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
    Jóri B; Falk M; Hövel I; Weist P; Tiemann M; Heukamp LC; Griesinger F
    Curr Oncol; 2022 Sep; 29(9):6628-6634. PubMed ID: 36135089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and preliminary PET imaging of
    Collier TL; Normandin MD; Stephenson NA; Livni E; Liang SH; Wooten DW; Esfahani SA; Stabin MG; Mahmood U; Chen J; Wang W; Maresca K; Waterhouse RN; El Fakhri G; Richardson P; Vasdev N
    Nat Commun; 2017 Jun; 8():15761. PubMed ID: 28594000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
    Chen J; O'Gorman MT; James LP; Klamerus KJ; Mugundu G; Pithavala YK
    Clin Pharmacokinet; 2021 Oct; 60(10):1313-1324. PubMed ID: 33937954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lorlatinib induced proteinuria: A case report.
    Lee CS; Wanchoo R; Seetharamu N
    J Oncol Pharm Pract; 2021 Jun; 27(4):1037-1039. PubMed ID: 32996364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.